Wells Fargo Maintains Equal-Weight on Editas Medicine, Raises Price Target to $4
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Yanan Zhu maintains Editas Medicine (NASDAQ:EDIT) with a Equal-Weight and raises the price target from $3 to $4.
Wells Fargo analyst Yanan Zhu maintains Editas Medicine (NASDAQ:EDIT) with a Equal-Weight and raises the price target from $3 to $4.